Correlation of the clinical pharmacodynamics of loprazolam with serum concentration. 1985

L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen

Six healthy fasted volunteers each received oral doses of a placebo, 1 mg and 2 mg loprazolam with one week between treatments using a double-blind balanced crossover design. Serum samples were obtained at selected times after dosing for measurement of loprazolam using a combined high-performance liquid and gas chromatographic assay. Drug effect was also measured at the corresponding times using self-assessment scales and psychomotor tests. The serum levels of loprazolam followed a somewhat irregular shape with secondary and tertiary peaks possibly associated with food intake. The maximum serum levels of loprazolam following 1 mg and 2 mg doses of the drug (6.0 +/- 2.6 and 11.3 +/- 2.9 ng/ml, respectively) occurred at approximately one hour after dosing. Both the maximum serum levels and the area under the curve of loprazolam measured to six hours increased in direct proportion to dose. Statistically significant drug effects were seen after 2 mg loprazolam, although the subjects also appeared sedated after 1 mg doses. There appeared to be a good correlation between the logarithm of the serum concentration of loprazolam and effect which suggested that the hypnotic activity of the drug was not mediated via a long-lived metabolite. A threshold serum concentration associated with evident sedation was observed at approximately 3 ng/ml.

UI MeSH Term Description Entries
D006993 Hypnotics and Sedatives Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. Hypnotic,Sedative,Sedative and Hypnotic,Sedatives,Hypnotic Effect,Hypnotic Effects,Hypnotics,Sedative Effect,Sedative Effects,Sedatives and Hypnotics,Effect, Hypnotic,Effect, Sedative,Effects, Hypnotic,Effects, Sedative,Hypnotic and Sedative
D008297 Male Males
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001569 Benzodiazepines A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. Benzodiazepine,Benzodiazepine Compounds
D001570 Benzodiazepinones
D012890 Sleep A readily reversible suspension of sensorimotor interaction with the environment, usually associated with recumbency and immobility. Sleep Habits,Sleeping Habit,Sleeping Habits,Habit, Sleep,Habit, Sleeping,Habits, Sleep,Habits, Sleeping,Sleep Habit
D014151 Anti-Anxiety Agents Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. Anti-Anxiety Agent,Anti-Anxiety Drug,Anxiolytic,Anxiolytic Agent,Anxiolytic Agents,Tranquilizing Agents, Minor,Anti-Anxiety Drugs,Anti-Anxiety Effect,Anti-Anxiety Effects,Antianxiety Effect,Antianxiety Effects,Anxiolytic Effect,Anxiolytic Effects,Anxiolytics,Tranquillizing Agents, Minor,Agent, Anti-Anxiety,Agent, Anxiolytic,Agents, Anti-Anxiety,Agents, Anxiolytic,Agents, Minor Tranquilizing,Agents, Minor Tranquillizing,Anti Anxiety Agent,Anti Anxiety Agents,Anti Anxiety Drug,Anti Anxiety Drugs,Anti Anxiety Effect,Anti Anxiety Effects,Drug, Anti-Anxiety,Drugs, Anti-Anxiety,Effect, Anti-Anxiety,Effect, Antianxiety,Effect, Anxiolytic,Effects, Anti-Anxiety,Effects, Antianxiety,Effects, Anxiolytic,Minor Tranquilizing Agents,Minor Tranquillizing Agents

Related Publications

L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
August 1985, British journal of clinical pharmacology,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
July 1974, Journal of immunology (Baltimore, Md. : 1950),
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
February 1991, Archives of disease in childhood,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
February 2018, Zhongguo shi yan xue ye xue za zhi,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
June 2011, Journal of clinical pharmacy and therapeutics,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
April 1988, Journal of clinical pharmacology,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
October 1991, Veterinary and human toxicology,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
January 1984, Contributions to nephrology,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
March 1972, The Journal of pharmacology and experimental therapeutics,
L A Stevens, and A W Pidgen, and C D Bevan, and R M Ings, and J R Lawrence, and J McEwen
June 2018, Tumori,
Copied contents to your clipboard!